Report cover image

Global CGRP Receptor Antagonists Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 195 Pages
SKU # APRC20280295

Description

Summary

According to APO Research, the global CGRP Receptor Antagonists market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for CGRP Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for CGRP Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the CGRP Receptor Antagonists market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for CGRP Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the CGRP Receptor Antagonists market include AbbVie Inc. and Pfizer Inc. etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for CGRP Receptor Antagonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of CGRP Receptor Antagonists, also provides the sales of main regions and countries. Of the upcoming market potential for CGRP Receptor Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CGRP Receptor Antagonists sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global CGRP Receptor Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for CGRP Receptor Antagonists sales, projected growth trends, production technology, application and end-user industry.

CGRP Receptor Antagonists Segment by Company

AbbVie Inc.
Pfizer Inc.
CGRP Receptor Antagonists Segment by Type

Oral
Nasal Spray
CGRP Receptor Antagonists Segment by Application

Hospital
Specialty Clinic
Others
CGRP Receptor Antagonists Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global CGRP Receptor Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions CGRP Receptor Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify CGRP Receptor Antagonists significant trends, drivers, influence factors in global and regions.
6. To analyze CGRP Receptor Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGRP Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Receptor Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the CGRP Receptor Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CGRP Receptor Antagonists industry.
Chapter 3: Detailed analysis of CGRP Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of CGRP Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of CGRP Receptor Antagonists in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global CGRP Receptor Antagonists Sales Value (2020-2031)
1.2.2 Global CGRP Receptor Antagonists Sales Volume (2020-2031)
1.2.3 Global CGRP Receptor Antagonists Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 CGRP Receptor Antagonists Market Dynamics
2.1 CGRP Receptor Antagonists Industry Trends
2.2 CGRP Receptor Antagonists Industry Drivers
2.3 CGRP Receptor Antagonists Industry Opportunities and Challenges
2.4 CGRP Receptor Antagonists Industry Restraints
3 CGRP Receptor Antagonists Market by Company
3.1 Global CGRP Receptor Antagonists Company Revenue Ranking in 2024
3.2 Global CGRP Receptor Antagonists Revenue by Company (2020-2025)
3.3 Global CGRP Receptor Antagonists Sales Volume by Company (2020-2025)
3.4 Global CGRP Receptor Antagonists Average Price by Company (2020-2025)
3.5 Global CGRP Receptor Antagonists Company Ranking (2023-2025)
3.6 Global CGRP Receptor Antagonists Company Manufacturing Base and Headquarters
3.7 Global CGRP Receptor Antagonists Company Product Type and Application
3.8 Global CGRP Receptor Antagonists Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global CGRP Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 CGRP Receptor Antagonists Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 CGRP Receptor Antagonists Market by Type
4.1 CGRP Receptor Antagonists Type Introduction
4.1.1 Oral
4.1.2 Nasal Spray
4.2 Global CGRP Receptor Antagonists Sales Volume by Type
4.2.1 Global CGRP Receptor Antagonists Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global CGRP Receptor Antagonists Sales Volume by Type (2020-2031)
4.2.3 Global CGRP Receptor Antagonists Sales Volume Share by Type (2020-2031)
4.3 Global CGRP Receptor Antagonists Sales Value by Type
4.3.1 Global CGRP Receptor Antagonists Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global CGRP Receptor Antagonists Sales Value by Type (2020-2031)
4.3.3 Global CGRP Receptor Antagonists Sales Value Share by Type (2020-2031)
5 CGRP Receptor Antagonists Market by Application
5.1 CGRP Receptor Antagonists Application Introduction
5.1.1 Hospital
5.1.2 Specialty Clinic
5.1.3 Others
5.2 Global CGRP Receptor Antagonists Sales Volume by Application
5.2.1 Global CGRP Receptor Antagonists Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global CGRP Receptor Antagonists Sales Volume by Application (2020-2031)
5.2.3 Global CGRP Receptor Antagonists Sales Volume Share by Application (2020-2031)
5.3 Global CGRP Receptor Antagonists Sales Value by Application
5.3.1 Global CGRP Receptor Antagonists Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global CGRP Receptor Antagonists Sales Value by Application (2020-2031)
5.3.3 Global CGRP Receptor Antagonists Sales Value Share by Application (2020-2031)
6 CGRP Receptor Antagonists Regional Sales and Value Analysis
6.1 Global CGRP Receptor Antagonists Sales by Region: 2020 VS 2024 VS 2031
6.2 Global CGRP Receptor Antagonists Sales by Region (2020-2031)
6.2.1 Global CGRP Receptor Antagonists Sales by Region: 2020-2025
6.2.2 Global CGRP Receptor Antagonists Sales by Region (2026-2031)
6.3 Global CGRP Receptor Antagonists Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global CGRP Receptor Antagonists Sales Value by Region (2020-2031)
6.4.1 Global CGRP Receptor Antagonists Sales Value by Region: 2020-2025
6.4.2 Global CGRP Receptor Antagonists Sales Value by Region (2026-2031)
6.5 Global CGRP Receptor Antagonists Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America CGRP Receptor Antagonists Sales Value (2020-2031)
6.6.2 North America CGRP Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe CGRP Receptor Antagonists Sales Value (2020-2031)
6.7.2 Europe CGRP Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific CGRP Receptor Antagonists Sales Value (2020-2031)
6.8.2 Asia-Pacific CGRP Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America CGRP Receptor Antagonists Sales Value (2020-2031)
6.9.2 South America CGRP Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa CGRP Receptor Antagonists Sales Value (2020-2031)
6.10.2 Middle East & Africa CGRP Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
7 CGRP Receptor Antagonists Country-level Sales and Value Analysis
7.1 Global CGRP Receptor Antagonists Sales by Country: 2020 VS 2024 VS 2031
7.2 Global CGRP Receptor Antagonists Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global CGRP Receptor Antagonists Sales by Country (2020-2031)
7.3.1 Global CGRP Receptor Antagonists Sales by Country (2020-2025)
7.3.2 Global CGRP Receptor Antagonists Sales by Country (2026-2031)
7.4 Global CGRP Receptor Antagonists Sales Value by Country (2020-2031)
7.4.1 Global CGRP Receptor Antagonists Sales Value by Country (2020-2025)
7.4.2 Global CGRP Receptor Antagonists Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.5.2 USA CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.5.3 USA CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.6.2 Canada CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.6.2 Mexico CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.8.2 Germany CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.9.2 France CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.9.3 France CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.10.2 U.K. CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.11.2 Italy CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.12.2 Spain CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.13.2 Russia CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.16.2 China CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.16.3 China CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.17.2 Japan CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.18.2 South Korea CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.19.2 India CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.19.3 India CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.20.2 Australia CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.22.2 Brazil CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.23.2 Argentina CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.24.2 Chile CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.25.2 Colombia CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.26.2 Peru CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.28.2 Israel CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.29.2 UAE CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.30.2 Turkey CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.31.2 Iran CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt CGRP Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.32.2 Egypt CGRP Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt CGRP Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 AbbVie Inc.
8.1.1 AbbVie Inc. Comapny Information
8.1.2 AbbVie Inc. Business Overview
8.1.3 AbbVie Inc. CGRP Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.1.4 AbbVie Inc. CGRP Receptor Antagonists Product Portfolio
8.1.5 AbbVie Inc. Recent Developments
8.2 Pfizer Inc.
8.2.1 Pfizer Inc. Comapny Information
8.2.2 Pfizer Inc. Business Overview
8.2.3 Pfizer Inc. CGRP Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.2.4 Pfizer Inc. CGRP Receptor Antagonists Product Portfolio
8.2.5 Pfizer Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 CGRP Receptor Antagonists Value Chain Analysis
9.1.1 CGRP Receptor Antagonists Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 CGRP Receptor Antagonists Sales Mode & Process
9.2 CGRP Receptor Antagonists Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 CGRP Receptor Antagonists Distributors
9.2.3 CGRP Receptor Antagonists Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.